1067647-43-1

1067647-43-1 structure

Name: 6,6-DIMETHYL-3-(5-METHYL-3-OXO-2-(4-(TRIFLUOROMETHOXY)PHENYL)-2,3-DIHYDRO-1H-PYRAZOL-4-YL)-1-PHENYL-3-(TRIFLUOROMETHYL)-6,7-DIHYDRO-1H-INDOLE-2,4(3H,5H)-DIONE
Chemical Name: 6,6-dimethyl-3-[5-methyl-3-oxo-2-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]-1-phenyl-3-(trifluoromethyl)-5,7-dihydroindole-2,4-dione
CAS Number: 1067647-43-1
Molecular Formula: C₂₈H₂₃F₆N₃O₄
Molecular Weight: 579.49000
Catalog: Research Areas Metabolic Disease
Create Date: 2017-03-30 17:38:02
Modify Date: 2024-01-27 22:29:32
ELOVL6-IN-2 is a potent, orally active and selective ELOVL6 inhibitor. ELOVL6-IN-2 inhibits mouse ELOVL6 activities, with an IC50 value of 34 nM[1].

Name	6,6-dimethyl-3-[5-methyl-3-oxo-2-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]-1-phenyl-3-(trifluoromethyl)-5,7-dihydroindole-2,4-dione

Description	ELOVL6-IN-2 is a potent, orally active and selective ELOVL6 inhibitor. ELOVL6-IN-2 inhibits mouse ELOVL6 activities, with an IC50 value of 34 nM[1].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease
Target	IC50: 34 nM (ELOVL6)[1]
In Vivo	ELOVL6-IN-2 (0.1~1mg/kg; p.o.; 2 hours) potently and dose-proportionally suppresses the elongation index in the liver[1]. ELOVL6-IN-2 (10mg/kg; p.o.; 2 hours) demonstrates highly liver penetrable[1]. ELOVL6-IN-2 (1mg/kg; p.o.; 2~24 hours) exhibits sustained plasma exposure[1]. Animal Model: Male C57BL/6J mice Dosage: 0.1~1mg/kg Administration: P.o Result: Potently and dose-proportionally suppressed the elongation index in the liver. Animal Model: Male C57BL/6J mice Dosage: 10 mg/kg Administration: P.o Result: Demonstrated highly liver penetrable. Animal Model: Male C57BL/6J mice Dosage: 1 mg/kg Administration: P.o Result: Exhibited sustained plasma exposure.
References	[1]. akahashi T, et al. Synthesis and evaluation of a novel indoledione class of long chain fatty acid elongase 6 (ELOVL6) inhibitors. J Med Chem. 2009;52(10):3142-3145.